LGND vs LNTH: fair value comparison
Ligand Pharmaceuticals Incorporated and Lantheus Holdings, Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, LNTH currently sits closer to the top of our discount ranking.
| LGND | LNTH | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $284.27 | $100.88 |
| 12-month range | $179.07–$312.01 | $51.63–$108.96 |
| Sector rank | #109 of 113 Healthcare | #104 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: LGND fair value analysis · LNTH fair value analysis